What this means
This is a plan to study a blood disease called MPN. Researchers will measure biological age and see if it links to clots and disease changes.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 1 site
The science
- Registered title
- Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
- Trial ID
- NCT06022328 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Myeloproliferative Neoplasm
- What is tested
- Assessment of the epigenetic age
- Sponsor
- University Hospital, Bordeaux
- Ages
- 18 Years to no maximum
- Dates
- First posted Sep 1, 2023 · updated Jul 30, 2025
Registry summary
Myeloproliferative Neoplasms (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. MPN can be complicated by thrombosis and evolution into more aggressive diseases (myelofibrosis and acute leukemia). Aging remains the principal factor determining patients' survival in MPN. In recent years, DNA methylation has appeared as a mean to measure aging via the development of epigenetic clocks that have also been associated with the occurrence of thrombosis and cancer. The epiC project aims at determining epigenetic age of MPN patients and search for an association between this parameter and thrombotic/hematological complications.
Sites (1)
- CHU de Bordeaux, service Hématologie Biologique, Bordeaux, France